ArticlePharmaceutical research2026
Development and Validation of an Efficient In vitro Bioassay for Potency Estimation of Recombinant Human Erythropoietin Formulations.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecombinant human erythropoietin (rHuEPO) is regarded as a life-saving biotherapeutic in case of acute disease associated anemia. Several commercially available rHuEPO drug products are present in the market for patient consumption. Since manufacturers use different technologies to produce recombinant drugs, their quality, safety and efficacy becomes imperative as compared with the innovator. Compendial guidelines worldwide have laid down regulations and testing methodologies to ascertain the potency of biomolecular drugs. The current method for potency estimation of rHuEPO samples is animal-based, lengthy, tedious, ethically restrained and shows high variability. The current study employs a rather simple cell-based method that can be used as an alternative to the in vivo methods.
methodsA cell proliferation method, with absorbance-based end point, was developed on UT-7 cell line for estimating the potency of rHuEPO products. The developed UT-7 cell line method was validated according to USP and ICH guidelines. The utility of method was further confirmed on different batches of rHuEPO drug products to determine their potency values. These batches simultaneously were analyzed by the existing in vivo method as cross validation studies.
resultsThe results showed high level of reproducibility, precision, accuracy and range. The comparative studies of in vitro with in vivo methods depicted the potency of the batches by both the methods were in the acceptable range of 80-125%
conclusionThough, this method doesn't account for the additional effects of a closed in vivo system, yet it presents itself as a simple and sensitive method that can be used for regular quality testing of rHuEPO formulations.
Indexed as
Identifiers
41792507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.